The decision to cut 60% of the workforce and focus on drug development is a significant strategic shift for Lexicon Pharmaceuticals. While this may reduce operational costs and potentially improve long-term prospects by focusing on core competencies, the immediate impact on stock price is uncertain. Investors may view the reduction in commercial activities as a negative, but the focus on drug development could be seen as a positive for future growth.